JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Search

Celldex Therapeutics Inc

Închisă

SectorSănătate

24.25 -3.54

Rezumat

Modificarea prețului

24h

Curent

Minim

23.9

Maxim

25.14

Indicatori cheie

By Trading Economics

Venit

-10M

-67M

Marjă de profit

-7,753.425

Angajați

186

EBITDA

-9.8M

-73M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+116.95% upside

Dividende

By Dow Jones

Următoarele câștiguri

25 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

260M

1.8B

Deschiderea anterioară

27.79

Închiderea anterioară

24.25

Sentimentul știrilor

By Acuity

50%

50%

152 / 352 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Celldex Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 feb. 2026, 23:11 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 feb. 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 feb. 2026, 23:50 UTC

Market Talk

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 feb. 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 feb. 2026, 23:41 UTC

Achiziții, Fuziuni, Preluări

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 feb. 2026, 23:38 UTC

Câștiguri

AMD Sales Climb on Help From Data-Center Business -- Update

3 feb. 2026, 23:29 UTC

Achiziții, Fuziuni, Preluări

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 feb. 2026, 23:27 UTC

Achiziții, Fuziuni, Preluări

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 feb. 2026, 23:25 UTC

Achiziții, Fuziuni, Preluări

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 feb. 2026, 23:23 UTC

Achiziții, Fuziuni, Preluări

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 feb. 2026, 23:22 UTC

Achiziții, Fuziuni, Preluări

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 feb. 2026, 23:19 UTC

Market Talk

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 feb. 2026, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

3 feb. 2026, 22:56 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 feb. 2026, 22:40 UTC

Câștiguri

Amdocs Extends Collaboration With T-Mobile

3 feb. 2026, 22:39 UTC

Câștiguri

Amdocs 1Q Adj EPS $1.81

3 feb. 2026, 22:39 UTC

Câștiguri

Amdocs 1Q Rev $1.16B

3 feb. 2026, 22:39 UTC

Câștiguri

Amdocs 1Q EPS $1.45 >

3 feb. 2026, 22:38 UTC

Câștiguri

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 feb. 2026, 22:30 UTC

Achiziții, Fuziuni, Preluări

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 feb. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 feb. 2026, 22:14 UTC

Câștiguri

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 feb. 2026, 22:13 UTC

Câștiguri

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 feb. 2026, 22:12 UTC

Câștiguri

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 feb. 2026, 22:10 UTC

Câștiguri

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 feb. 2026, 22:10 UTC

Câștiguri

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 feb. 2026, 22:10 UTC

Market Talk

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 feb. 2026, 22:10 UTC

Câștiguri

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 feb. 2026, 22:09 UTC

Câștiguri

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 feb. 2026, 22:09 UTC

Câștiguri

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Comparație

Modificare preț

Celldex Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

116.95% sus

Prognoză pe 12 luni

Medie 53.5 USD  116.95%

Maxim 90 USD

Minim 24 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCelldex Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

8

Cumpărare

0

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

18.91 / 20.63Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

152 / 352 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat